Emergent Biosolutions (NYSE:EBS) Stock: Insider Donald Degolyer Sells 17,800 Shares

Emergent Biosolutions Inc. (NYSE:EBS) Director Donald Degolyer sold 17,800 shares of the business’s stock in a transaction on Wednesday, October 7th. The shares were sold at an average price of $7.09, for a total transaction of $126,202.00. Following the completion of the transaction, the director directly owned 111,921 shares in the company, valued at $793,519.89. This represents a 13.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Stock Performance

Shares of EBS stock traded up $0.13 during mid-day trading on Wednesday, hitting $7.08. The stock had a trading volume of 1,234,137 shares, compared to its average volume of 973,412. The firm has a market cap of $362.96 million, a PE ratio of -1.99 and a beta of 2.28. The company’s 50-day simple moving average is $6.10 and its 200-day simple moving average is $7.47. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95. Emergent Biosolutions Inc. has a fifty-two week low of $4.36 and a fifty-two week high of $14.06.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.68. The company had revenue of $234.30 million for the quarter, compared to analysts’ expectations of $177.50 million. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. Sell-side analysts anticipate that Emergent Biosolutions Inc. will post 0.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on EBS shares. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Emergent Biosolutions in a research note on Wednesday, September 9th. Weiss Ratings raised shares of Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, August 21st. JPMorgan Chase & Co. began coverage on shares of Emergent Biosolutions in a research report on Friday, August 21st. They set an “underweight” rating on the stock. Finally, Zacks Research raised shares of Emergent Biosolutions to a “hold” rating in a report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.

Institutional Investors Weigh In On Emergent Biosolutions

A number of large investors have recently bought and sold shares of EBS. WINTON GROUP Ltd raised its holdings in shares of Emergent Biosolutions by 243.2% in the second quarter. WINTON GROUP Ltd now owns 45,744 shares of the biopharmaceutical company’s stock worth $383,000 after acquiring an additional 32,415 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in shares of Emergent Biosolutions during the second quarter worth about $29,000. Ancora Advisors LLC raised its position in shares of Emergent Biosolutions by 160.9% in the second quarter. Ancora Advisors LLC now owns 1,067,867 shares of the biopharmaceutical company’s stock valued at $8,949,000 after buying an additional 658,600 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of Emergent Biosolutions in the second quarter valued at approximately $36,000. Finally, Bank of America Corp DE purchased a new position in shares of Emergent Biosolutions during the second quarter valued at approximately $1,276,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc (NYSE:EBS) is a life sciences company focused on developing, manufacturing and supplying medical countermeasures for public health threats, including chemical, biological, radiological and nuclear hazards, as well as infectious diseases. The company serves government agencies, healthcare providers and commercial customers.

Emergent’s portfolio has included vaccines, therapeutics and other products used to prevent or treat serious health threats. Its offerings include BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine, along with products such as botulism antitoxin and vaccinia immune globulin.